BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Etavopivat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Etavopivat\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05953584-10273@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:Etavopivat: Phase 2 readout est. (NCT05953584)
DESCRIPTION:Etavopivat\, phase 2\, Sickle Cell Disease.\nStudy: A Phase 2 O
 pen-label Study to Evaluate the Activity of Etavopivat on Transcranial Dop
 pler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at 
 Increased Risk for Primary Stroke\nEstimated primary completion: 20 August
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/etavopivat#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0595358
 4
URL:https://assetmemo.bio/drug/etavopivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612268-10273@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270827
DTEND;VALUE=DATE:20270828
SUMMARY:Etavopivat: Phase 3 readout est. (NCT06612268)
DESCRIPTION:Etavopivat\, phase 3\, Sickle Cell Disease.\nStudy: A Study to 
 Evaluate How Well Etavopivat Works in People With Sickle Cell Disease\nEst
 imated primary completion: 27 August 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/etavopivat#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06612268
URL:https://assetmemo.bio/drug/etavopivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06198712-10273@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280223
DTEND;VALUE=DATE:20280224
SUMMARY:Etavopivat: Phase 2 readout est. (NCT06198712)
DESCRIPTION:Etavopivat\, phase 2\, Sickle Cell Disease.\nStudy: A Study to 
 Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patien
 ts With Sickle Cell Disease\nEstimated primary completion: 23 February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/etavopivat#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06198712
URL:https://assetmemo.bio/drug/etavopivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06609226-10273@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Etavopivat: Phase 3 readout est. (NCT06609226)
DESCRIPTION:Etavopivat\, phase 3\, Sickle Cell Disease.\nStudy: A Research 
 Study Looking at Long-term Treatment With Etavopivat in People With Sickle
  Cell Disease or Thalassaemia\nEstimated primary completion: 30 December 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/etavopivat#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06609226
URL:https://assetmemo.bio/drug/etavopivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
